Skip to content

Predictors of Improvement and Deterioration of Community Acquired Pneumonia in Children

Predictors of Improvement and Deterioration of Community Acquired Pneumonia in Children

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06720441
Enrollment
70
Registered
2024-12-06
Start date
2025-01-01
Completion date
2026-01-01
Last updated
2024-12-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Predictors of Improvement and Deterioration of Community Acquired Pneumonia

Brief summary

Predictors of improvement and deterioration of community acquired pneumonia in children Community-acquired pneumonia (CAP) is the most prevalent respiratory infectious disease. It is defined as an acute infection of the lung parenchyma that is acquired outside the hospital. Community-acquired pneumonia (CAP) is one of the most common disorders faced in clinical practice . \[1,2\] Childhood CAP is the leading cause of death in children younger than five years globally\[3\] . Acute phase reactants (APR) are inflammatory mediators that show significant alternations in serum levels in response to inflammation, these markers are responsible for some adverse effects such as anorexia, fever, fatigue, and anemia of chronic illness \[4\] APR can be applied for the assessment of disease severity in CAP in collaboration with clinical evaluation and pneumonia severity scores \[5\]. The most common APR are (NLR), CRP, and ESR, changes in the level of these indices can be used in the diagnosis and prognosis of inflammatory and infectious diseases \[5\] NLR is a rapid, simple, and cheap maker of the systemic inflammatory process, it is calculated as the ratio between neutrophil count to lymphocyte count from peripheral blood sample. Numerous researches have assessed the role of NLR in many infectious diseases such as sepsis, bacteremia, and septic shock, in addition, it can predict the severity and outcome of CAP \[6\] CRP is one of the best indicators of the acute phase response to inflammation. This serum protein is synthesized by hepatocytes and is classified as an acute-phase protein based on its increased serum concentration during inflammation and infection\[7\] So, the aim of the current study was to assess levels of APR such as total leucocytic count (TLC), platelets, neutrophils, neutrophils-to-lymphocyte ratio (NLR), CRP, D-dimer, Ferritin, and ESR in patients with CAP (as a primary outcome) and to correlate between their measured values and disease severity (as a secondary outcome)

Detailed description

Assessment of community-acquired pneumonia (CAP) severity in association with various pneumonia severity scores. So, the aim of the study was to assess levels of APR such as total leucocytic count (TLC), platelets, neutrophils, neutrophils-to-lymphocyte ratio (NLR), CRP, D-dimer, ferritin, and ESR in patients with CAP and to correlate between their values and disease severity.

Interventions

None listed

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
1 Months to 18 Years
Healthy volunteers
Yes

Inclusion criteria

All patients above a month and below 18 years old, both sexes, fulfilling diagnosis of CAP

Exclusion criteria

* Non-pulmonary infections, liver, renal, and cardiac diseases.and neonates with age less than a month

Design outcomes

Primary

MeasureTime frameDescription
Relation between acute phase reactants and pneumonia1 yearAssess levels of APR such as total leucocytic count (TLC), platelets, neutrophils, neutrophils-to-lymphocyte ratio (NLR), CRP, D-dimer, Ferritin, and ESR in patients with CAP (as a primary outcome)

Secondary

MeasureTime frameDescription
Predictors of improvement and deterioration of community acquired pneumonia in children1 yearPredictors of improvement and deterioration of community acquired pneumonia in children

Contacts

Primary ContactMarina Nageh MNTEshak, Resident physician
marinanageh918@gmail.com+1068215088
Backup ContactYasser Faruok YFAbderahim, Assistant professor
Yasser.rezk@aun.edu.eg+0 111 116 8123

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026